Cargando…

Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis

BACKGROUND: Aberrant cytokeratin 7 expression by hepatocytes (CK7(+)Hs) is the hallmark characteristic of cholestasis diseases, especially in ductopenia diseases such as primary biliary cholangitis (PBC). This study attempted to evaluate the differences and relationships between the clinical and his...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hong-Li, Yang, An-Yin, Xiong, Qing-Fang, Zhong, Yan-Dan, Liu, Du-Xian, Huang, Ping, Feng, Xiao-Ning, Zhang, Yu, Yang, Yong-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628093/
https://www.ncbi.nlm.nih.gov/pubmed/36324070
http://dx.doi.org/10.1186/s12876-022-02538-w
_version_ 1784823122846810112
author Liu, Hong-Li
Yang, An-Yin
Xiong, Qing-Fang
Zhong, Yan-Dan
Liu, Du-Xian
Huang, Ping
Feng, Xiao-Ning
Zhang, Yu
Yang, Yong-Feng
author_facet Liu, Hong-Li
Yang, An-Yin
Xiong, Qing-Fang
Zhong, Yan-Dan
Liu, Du-Xian
Huang, Ping
Feng, Xiao-Ning
Zhang, Yu
Yang, Yong-Feng
author_sort Liu, Hong-Li
collection PubMed
description BACKGROUND: Aberrant cytokeratin 7 expression by hepatocytes (CK7(+)Hs) is the hallmark characteristic of cholestasis diseases, especially in ductopenia diseases such as primary biliary cholangitis (PBC). This study attempted to evaluate the differences and relationships between the clinical and histological features of aberrant cytokeratin 7 (CK7) expression by hepatocytes in PBC patients. METHODS: The clinicopathological data of patients diagnosed with PBC at the Second Hospital of Nanjing between January 2016 and September 2018 were analysed with SPSS 20.0. RESULTS: Eighty-nine PBC patients who underwent liver biopsy were enrolled in this study, and 15, 29 and 45 patients had aberrant CK7 expression by hepatocytes (CK7(+)Hs (2 +), CK7(+)Hs (1 +), and CK7(−)Hs, respectively). There were significant differences in TB, DB, ALP, TA, IgM, interface activity, and ductopenia grade between patients with CK7(−)Hs and CK7(+)Hs (2 +) (P < 0.05). The ductopenia grade was also significantly different between patients with CK7(+)Hs (2 +) and CK7(+)Hs (1 +) according to sex (P < 0.05). Upon merging the data of CK7(+)Hs (2 +) and CK7(+)Hs (1 +) into CK7(+)Hs, we found significant differences in AMA, AMA-M2, anti-gp210, TB, DB, ALP, TA, IgM, fibrosis, and ductopenia grade between CK7(+)Hs and CK7(−)Hs (P < 0.05). The odds ratios (ORs) (and 95% confidence intervals (CIs)) of CK7(+)Hs according to anti-gp210, ductopenia grade, and interface activity were 6.413 (95% CI 1.363–30.162), 4.145 (95% CI 1.898–9.052) and 3.247 (95% CI 1.556–6.775), respectively (P < 0.05). Spearman's rank correlation according to interface activity and ductopenia grade in patients with CK7(+)Hs (2 + , 1 + , 0) was r = 0.359 (P = 0.001) and r = 0.396 (P < 0.001), respectively. CONCLUSION: CK7(+)Hs serves as a cholestasis index of PBC and are associated with the ductopenia grade and interface activity. Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis.
format Online
Article
Text
id pubmed-9628093
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96280932022-11-03 Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis Liu, Hong-Li Yang, An-Yin Xiong, Qing-Fang Zhong, Yan-Dan Liu, Du-Xian Huang, Ping Feng, Xiao-Ning Zhang, Yu Yang, Yong-Feng BMC Gastroenterol Research BACKGROUND: Aberrant cytokeratin 7 expression by hepatocytes (CK7(+)Hs) is the hallmark characteristic of cholestasis diseases, especially in ductopenia diseases such as primary biliary cholangitis (PBC). This study attempted to evaluate the differences and relationships between the clinical and histological features of aberrant cytokeratin 7 (CK7) expression by hepatocytes in PBC patients. METHODS: The clinicopathological data of patients diagnosed with PBC at the Second Hospital of Nanjing between January 2016 and September 2018 were analysed with SPSS 20.0. RESULTS: Eighty-nine PBC patients who underwent liver biopsy were enrolled in this study, and 15, 29 and 45 patients had aberrant CK7 expression by hepatocytes (CK7(+)Hs (2 +), CK7(+)Hs (1 +), and CK7(−)Hs, respectively). There were significant differences in TB, DB, ALP, TA, IgM, interface activity, and ductopenia grade between patients with CK7(−)Hs and CK7(+)Hs (2 +) (P < 0.05). The ductopenia grade was also significantly different between patients with CK7(+)Hs (2 +) and CK7(+)Hs (1 +) according to sex (P < 0.05). Upon merging the data of CK7(+)Hs (2 +) and CK7(+)Hs (1 +) into CK7(+)Hs, we found significant differences in AMA, AMA-M2, anti-gp210, TB, DB, ALP, TA, IgM, fibrosis, and ductopenia grade between CK7(+)Hs and CK7(−)Hs (P < 0.05). The odds ratios (ORs) (and 95% confidence intervals (CIs)) of CK7(+)Hs according to anti-gp210, ductopenia grade, and interface activity were 6.413 (95% CI 1.363–30.162), 4.145 (95% CI 1.898–9.052) and 3.247 (95% CI 1.556–6.775), respectively (P < 0.05). Spearman's rank correlation according to interface activity and ductopenia grade in patients with CK7(+)Hs (2 + , 1 + , 0) was r = 0.359 (P = 0.001) and r = 0.396 (P < 0.001), respectively. CONCLUSION: CK7(+)Hs serves as a cholestasis index of PBC and are associated with the ductopenia grade and interface activity. Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis. BioMed Central 2022-11-02 /pmc/articles/PMC9628093/ /pubmed/36324070 http://dx.doi.org/10.1186/s12876-022-02538-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Liu, Hong-Li
Yang, An-Yin
Xiong, Qing-Fang
Zhong, Yan-Dan
Liu, Du-Xian
Huang, Ping
Feng, Xiao-Ning
Zhang, Yu
Yang, Yong-Feng
Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis
title Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis
title_full Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis
title_fullStr Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis
title_full_unstemmed Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis
title_short Aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis
title_sort aberrant cytokeratin 7 expression by hepatocytes can predict the ductopenia grade in primary biliary cholangitis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9628093/
https://www.ncbi.nlm.nih.gov/pubmed/36324070
http://dx.doi.org/10.1186/s12876-022-02538-w
work_keys_str_mv AT liuhongli aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis
AT yanganyin aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis
AT xiongqingfang aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis
AT zhongyandan aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis
AT liuduxian aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis
AT huangping aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis
AT fengxiaoning aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis
AT zhangyu aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis
AT yangyongfeng aberrantcytokeratin7expressionbyhepatocytescanpredicttheductopeniagradeinprimarybiliarycholangitis